Department of Internal Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.
Probiotics Antimicrob Proteins. 2019 Dec;11(4):1248-1256. doi: 10.1007/s12602-018-9499-3.
This study was conducted to evaluate the effects of synbiotic supplementation on metabolic profiles in diabetic patients undergoing hemodialysis (HD). This randomized, double-blinded, placebo-controlled clinical trial was performed in 60 diabetic HD patients. Participants were randomly assigned into two groups to receive either synbiotic capsule, containing Lactobacillus acidophilus, Lactobacillus casei, and Bifidobacterium bifidum (2 × 10 CFU/g each), plus 0.8 g/day of inulin (n = 30) or placebo (n = 30) for 12 weeks. Synbiotic supplementation significantly decreased fasting plasma glucose (β - 13.56 mg/dL; 95% CI, - 23.82, - 3.30; P = 0.01), insulin levels (β - 5.49 μIU/mL; 95% CI, - 6.92, - 4.05; P < 0.001), and insulin resistance (β - 2.25; 95% CI, - 3.02, - 1.48; P < 0.001), while increased the quantitative insulin sensitivity check index (β 0.02; 95% CI, 0.01, 0.02; P < 0.001) compared with the placebo. Additionally, synbiotic intake resulted in a significant reduction in high-sensitivity C-reactive protein (β - 2930.48 ng/mL; 95% CI, - 3741.15, - 2119.80; P < 0.001) and malondialdehyde levels (β - 0.60 μmol/L; 95% CI, - 0.99, - 0.20; P = 0.003). Moreover, we found a significant increase in total antioxidant capacity (β 142.99 mmol/L; 95% CI, 61.72, 224.25; P = 0.001) and total glutathione levels (β 131.11 μmol/L; 95% CI, 89.35, 172.87; P < 0.001) in the synbiotic group compared with the placebo group. Overall, synbiotic supplementation for 12 weeks had beneficial effects on glycemic control, biomarkers of inflammation, and oxidative stress in diabetic patients under HD. This study was registered in the Iranian website (www.irct.ir) for registration of clinical trials (http://www.irct.ir: IRCT2017090133941N17). http://www.irct.ir: IRCT2017090133941N17.
这项研究旨在评估益生菌补充剂对接受血液透析（HD）的糖尿病患者代谢谱的影响。这是一项随机、双盲、安慰剂对照的临床试验，在 60 名糖尿病 HD 患者中进行。参与者被随机分配到两组，分别接受含有嗜酸乳杆菌、干酪乳杆菌和双歧杆菌（每种 2×10 CFU/g）的益生菌胶囊，外加 0.8 克/天菊粉（n=30）或安慰剂（n=30），持续 12 周。与安慰剂组相比，益生菌补充剂显著降低了空腹血糖（β - 13.56 mg/dL；95%CI，- 23.82，- 3.30；P = 0.01）、胰岛素水平（β - 5.49 μIU/mL；95%CI，- 6.92，- 4.05；P < 0.001）和胰岛素抵抗（β - 2.25；95%CI，- 3.02，- 1.48；P < 0.001），同时增加了定量胰岛素敏感性检查指数（β 0.02；95%CI，0.01，0.02；P < 0.001）。此外，益生菌摄入导致高敏 C 反应蛋白（β - 2930.48 ng/mL；95%CI，- 3741.15，- 2119.80；P < 0.001）和丙二醛水平（β - 0.60 μmol/L；95%CI，- 0.99，- 0.20；P = 0.003）显著降低。此外，我们发现与安慰剂组相比，益生菌组的总抗氧化能力（β 142.99 mmol/L；95%CI，61.72，224.25；P = 0.001）和总谷胱甘肽水平（β 131.11 μmol/L；95%CI，89.35，172.87；P < 0.001）显著增加。总的来说，益生菌补充剂治疗 12 周对 HD 糖尿病患者的血糖控制、炎症生物标志物和氧化应激有有益影响。这项研究在伊朗网站（www.irct.ir）上进行了登记（http://www.irct.ir：IRCT2017090133941N17）。http://www.irct.ir：IRCT2017090133941N17.
